MAPK3 and neoplasm: IL-17A and its receptors are expressed across different tumor types and contribute to a protumor niche via different pathways, such as promoting tumor chemoresistance and proliferation through extracellular signal-regulated kinase 1/2 (ERK1/2) in breast cancer [8].